Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Cash & Equivalents (2016 - 2025)

Avanos Medical (AVNS) has disclosed Cash & Equivalents for 13 consecutive years, with $89.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 16.62% to $89.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $89.8 million through Dec 2025, down 16.62% year-over-year, with the annual reading at $89.8 million for FY2025, 16.62% down from the prior year.
  • Cash & Equivalents hit $89.8 million in Q4 2025 for Avanos Medical, up from $70.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $127.7 million in Q4 2022 to a low of $70.5 million in Q3 2025.
  • Historically, Cash & Equivalents has averaged $97.8 million across 5 years, with a median of $97.4 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: crashed 46.67% in 2021 and later grew 27.97% in 2025.
  • Year by year, Cash & Equivalents stood at $118.5 million in 2021, then increased by 7.76% to $127.7 million in 2022, then plummeted by 31.32% to $87.7 million in 2023, then rose by 22.81% to $107.7 million in 2024, then decreased by 16.62% to $89.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for AVNS at $89.8 million in Q4 2025, $70.5 million in Q3 2025, and $90.3 million in Q2 2025.